ADIPOQ and metabolic syndrome: In RA patients undergoing anti-TNF infliximab therapy because of severe disease, high-grade inflammation shows an independent and negative correlation with circulating adiponectin concentrations, whereas low adiponectin levels clustered with MS features such as dyslipidemia and high plasma glucose levels that have been reportedly to contribute to atherogenesis in RA [69].